Fundamental Analysis

PROCTER & GAMBLE HEALTH LTD 

{Ticker : 500126 { BUY: Rs 4442.85 { Target: Rs 4900 

Procter & Gamble Health Limited is engaged in the manufacturing and marketing of pharmaceuticals, bulk drugs, fine chemicals and pigments. Its pharmaceutical segment consists of ethicals used in the treatment of cardiovascular and metabolic diseases, consumer healthcare products and vitamins-based formulations. On a standalone quarterly front, the company reported net sales of Rs 859.27 crore in Q2CY20, an increase of 5.04 per cent over Rs 818.07 crore recorded in Q2CY19. Operating profit for Q2CY20 was Rs 195.72 crore, decreasing by 2.37 per cent from Rs 202.89 crore reported in the corresponding quarter for the previous fiscal year. Net profit saw a growth of 9.51 per cent to Rs 135.93 crore in Q2CY20, from Rs 124.12 crore in Q2CY19. 

The demand for healthcare products has soared to record levels because of the demand spurred by the outbreak of Coronavirus, which bodes well for the company in terms of revenue growth. As a result, we recommend a BUY.